BioCentury | Mar 21, 2011
Finance

Eyes and ears

...co-invested a $30 million fund for Masa Life Science Ventures. MSLV's portfolio includes dermatology company MediQuest Therapeutics Inc....
BioCentury | Jun 8, 2009
Financial News

MediQuest completes venture financing

...Autoimmune, Infectious Date completed: 5/1/09 Type: Venture financing Raised: $23 million Investors: Not disclosed Note: MediQuest...
BioCentury | Jun 2, 2009
Financial News

MediQuest raises $23 million

...MediQuest Therapeutics Inc. (Bothell, Wash.) said it raised $23 million in a series B round. MediQuest...
BioCentury | Apr 9, 2009
Distillery Therapeutics

This week in therapeutics

...page 5). SciBX 2(14); doi:10.1038/scibx.2009.575 Published online April 9, 2009 Polyamine transport inhibitors patented by MediQuest Therapeutics Inc....
BioCentury | Apr 9, 2009
Targets & Mechanisms

Next-gen polyamine attack

...plus DFMO to treat SCCHN. Burns characterized the lysine-spermine conjugates while he was working at MediQuest Therapeutics Inc....
...Last year, he left the company and formed Aminex, which holds an exclusive license from MediQuest...
...Seattle, Wash. Cancer Prevention Pharmaceuticals LLC , Tucson, Ariz. Genzyme Corp. (NASDAQ:GENZ), Cambridge, Mass. MediQuest Therapeutics Inc....
BioCentury | Nov 3, 2008
Clinical News

MQX-503 regulatory update

...not disclose the contents of the letter. Vascana is a topical gel formulation of nitroglycerin. MediQuest Therapeutics Inc....
BioCentury | Nov 1, 2008
Company News

Vascana gets complete response letter

MediQuest (Bothell, Wash.) said FDA issued a complete response letter for an NDA for Vascana ( MQX-503 ) to treat Raynaud's disease, a circulatory disorder that affects the extremities. The company did not disclose the contents of...
BioCentury | Jul 7, 2008
Finance

2H milestones

...4Q08 Medarex (NASDAQ:MEDX)/ Novartis (NYSE:NVS; SWX:NOVN) ACZ885 Cryopyrin-associated periodic syndromes (CAPS) Ph III data YE08 MediQuest...
BioCentury | Jun 30, 2008
Clinical News

MQX-503 regulatory update

...FDA accepted for filing and granted Priority Review to an NDA from MediQuest for MQX-503 to...
...disease. The PDUFA date is Oct. 28. MQX-503 is a topical gel formulation of nitroglycerin. MediQuest Therapeutics Inc....
BioCentury | Jun 26, 2008
Company News

MediQuest's MQX-503 gets Priority Review

...FDA accepted for filing and granted Priority Review to an NDA from MediQuest (Bothell, Wash.) for...
Items per page:
1 - 10 of 33
BioCentury | Mar 21, 2011
Finance

Eyes and ears

...co-invested a $30 million fund for Masa Life Science Ventures. MSLV's portfolio includes dermatology company MediQuest Therapeutics Inc....
BioCentury | Jun 8, 2009
Financial News

MediQuest completes venture financing

...Autoimmune, Infectious Date completed: 5/1/09 Type: Venture financing Raised: $23 million Investors: Not disclosed Note: MediQuest...
BioCentury | Jun 2, 2009
Financial News

MediQuest raises $23 million

...MediQuest Therapeutics Inc. (Bothell, Wash.) said it raised $23 million in a series B round. MediQuest...
BioCentury | Apr 9, 2009
Distillery Therapeutics

This week in therapeutics

...page 5). SciBX 2(14); doi:10.1038/scibx.2009.575 Published online April 9, 2009 Polyamine transport inhibitors patented by MediQuest Therapeutics Inc....
BioCentury | Apr 9, 2009
Targets & Mechanisms

Next-gen polyamine attack

...plus DFMO to treat SCCHN. Burns characterized the lysine-spermine conjugates while he was working at MediQuest Therapeutics Inc....
...Last year, he left the company and formed Aminex, which holds an exclusive license from MediQuest...
...Seattle, Wash. Cancer Prevention Pharmaceuticals LLC , Tucson, Ariz. Genzyme Corp. (NASDAQ:GENZ), Cambridge, Mass. MediQuest Therapeutics Inc....
BioCentury | Nov 3, 2008
Clinical News

MQX-503 regulatory update

...not disclose the contents of the letter. Vascana is a topical gel formulation of nitroglycerin. MediQuest Therapeutics Inc....
BioCentury | Nov 1, 2008
Company News

Vascana gets complete response letter

MediQuest (Bothell, Wash.) said FDA issued a complete response letter for an NDA for Vascana ( MQX-503 ) to treat Raynaud's disease, a circulatory disorder that affects the extremities. The company did not disclose the contents of...
BioCentury | Jul 7, 2008
Finance

2H milestones

...4Q08 Medarex (NASDAQ:MEDX)/ Novartis (NYSE:NVS; SWX:NOVN) ACZ885 Cryopyrin-associated periodic syndromes (CAPS) Ph III data YE08 MediQuest...
BioCentury | Jun 30, 2008
Clinical News

MQX-503 regulatory update

...FDA accepted for filing and granted Priority Review to an NDA from MediQuest for MQX-503 to...
...disease. The PDUFA date is Oct. 28. MQX-503 is a topical gel formulation of nitroglycerin. MediQuest Therapeutics Inc....
BioCentury | Jun 26, 2008
Company News

MediQuest's MQX-503 gets Priority Review

...FDA accepted for filing and granted Priority Review to an NDA from MediQuest (Bothell, Wash.) for...
Items per page:
1 - 10 of 33